Raymond James Financial Services Advisors Inc. Has $1.92 Million Stock Holdings in Organon & Co. (NYSE:OGN)

Raymond James Financial Services Advisors Inc. lowered its stake in Organon & Co. (NYSE:OGN – Get Rating) by 9.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 68,709 shares of the company’s stock after selling 7,125 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Organon & Co. were worth $1,919,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of OGN. Fairfield Bush & CO. increased its stake in shares of Organon & Co. by 3.0% during the 1st quarter. Fairfield Bush & CO. now owns 16,302 shares of the company’s stock worth $569,000 after purchasing an additional 481 shares during the last quarter. Natixis Advisors L.P. raised its stake in Organon & Co. by 52.5% in the first quarter. Natixis Advisors L.P. now owns 50,428 shares of the company’s stock valued at $1,761,000 after buying an additional 17,370 shares during the period. MetLife Investment Management LLC lifted its position in shares of Organon & Co. by 23.2% in the first quarter. MetLife Investment Management LLC now owns 68,987 shares of the company’s stock valued at $2,410,000 after buying an additional 12,969 shares during the last quarter. Panagora Asset Management Inc. boosted its stake in shares of Organon & Co. by 95.6% during the 1st quarter. Panagora Asset Management Inc. now owns 39,595 shares of the company’s stock worth $1,383,000 after acquiring an additional 19,352 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Organon & Co. by 6.6% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,926 shares of the company’s stock worth $1,185,000 after acquiring an additional 2,101 shares during the last quarter. Institutional investors own 75.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Raymond James assumed coverage on shares of Organon & Co. in a research report on Wednesday, March 15th. They set an “outperform” rating and a $33.00 price objective for the company.

Organon & Co. Trading Down 2.5 %

Organon & Co. stock opened at $20.12 on Thursday. The company has a market capitalization of $5.13 billion, a price-to-earnings ratio of 6.89, a PEG ratio of 0.89 and a beta of 0.77. Organon & Co. has a 12 month low of $19.87 and a 12 month high of $39.09. The stock’s 50 day moving average is $22.64 and its 200-day moving average is $25.62.

Organon & Co. (NYSE:OGN – Get Rating) last issued its quarterly earnings data on Thursday, May 4th. The company reported $1.08 EPS for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.10). The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.54 billion. Organon & Co. had a net margin of 12.14% and a negative return on equity of 119.00%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.65 earnings per share. As a group, equities research analysts predict that Organon & Co. will post 4.22 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Monday, May 15th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 5.57%. The ex-dividend date is Friday, May 12th. Organon & Co.’s dividend payout ratio is 38.36%.

About Organon & Co.

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.